Alvotech (ALVO) Share-based Compensation (2022 - 2026)
Alvotech (ALVO) posted Share-based Compensation of $2.3 million for Q1 2026, up 566.0% on a QoQ basis from -$503000.0 in Q4 2025, and up 79.2% year-over-year from $1.3 million in Q1 2025.
Alvotech (ALVO) Share-based Compensation (2022 - 2026) Analysis & Trends
Alvotech's Share-based Compensation history runs 5 years deep, the most recent figure standing at $2.3 million for Q1 2026.
- Quarterly Share-based Compensation rose 79.2% year-over-year to $2.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.4 million (up 37.8% YoY) and the FY2025 annual result came in at $7.4 million, down 3.25% from the prior year.
- Share-based Compensation was $2.3 million for Q1 2026 at Alvotech, up from -$503000.0 in the prior quarter.
- Across five years, Share-based Compensation topped out at $6.4 million in Q1 2023 and bottomed at -$503000.0 in Q4 2025.
- A 5-year average of $2.8 million and a median of $2.6 million in 2024 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2023 — Share-based Compensation jumped 253.95% — and 2024, when it sank 109.0%.
- Alvotech's Share-based Compensation stood at $4.6 million in 2022, then plunged by 38.8% to $2.8 million in 2023, then plunged by 109.0% to -$255000.0 in 2024, then tumbled by 97.25% to -$503000.0 in 2025, then soared by 566.0% to $2.3 million in 2026.
- Business Quant data shows ALVO's Share-based Compensation at $2.3 million in Q1 2026, -$503000.0 in Q4 2025, and $4.5 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 43.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 25.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 125.69 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 58.30 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 56.50 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 55.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 21.00 Mn |
| 10 | Alvotech | 935.87 Mn | 935.87 Mn | 5.09 Mn | 2.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.34 Mn |
| Mar 31, 2026 | 2.34 Mn |
| Dec 31, 2025 | -503,000.00 |
| Dec 31, 2025 | -503,000.00 |
| Sep 30, 2025 | 4.46 Mn |
| Sep 30, 2025 | 4.46 Mn |
| Jun 30, 2025 | 2.11 Mn |
| Jun 30, 2025 | 2.11 Mn |
| Mar 31, 2025 | 1.31 Mn |
| Mar 31, 2025 | 1.31 Mn |
| Dec 31, 2024 | -255,000.00 |
| Dec 31, 2024 | -255,000.00 |
| Sep 30, 2024 | 2.59 Mn |
| Sep 30, 2024 | 2.59 Mn |
| Jun 30, 2024 | 2.47 Mn |
| Jun 30, 2024 | 2.47 Mn |
| Mar 31, 2024 | 2.83 Mn |
| Mar 31, 2024 | 2.83 Mn |
| Dec 31, 2023 | 2.83 Mn |
| Dec 31, 2023 | 2.83 Mn |